Patent search ap:("ABBOTT LAB") AND inv:"HUTCHINS CHARLES W" Page 6

51.

发明专利
COMPUESTOS ANTIVIRALES. 未知

公开(公告)号：MX2011006332A

公开(公告)日：2011-06-27

申请号：MX2011006332

申请日：2009-12-22

Applicant: ABBOTT LAB

Inventor： DONNER PAMELA L , DEGOEY DAVID A , HUTCHINS CHARLES W , JINKERSON TAMMIE K , KATI WARREN M , MATULENKO MARK A , KEDDY RYAN G

IPC: C07D471/04 , A61K31/519 , A61P31/14

Abstract: Se describen compuestos efectivos para inhibir la réplica de virus Hepatitis C ("HCV"). La presente invención también se refiere a procesos para elaborar dichos compuestos, composiciones que comprenden dichos compuestos, y métodos para utilizar dichos compuestos para tratar infección HCV.

52.

发明专利
PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF 未知

公开(公告)号：CA2728909A1

公开(公告)日：2010-01-14

申请号：CA2728909

申请日：2009-07-08

Applicant: ABBOTT LAB

Inventor： GU JIJIE , HUTCHINS CHARLES W , ZHU RONG-RONG , SHEN JIANWEI , HARRIS MARIA C , BELANGER EILEEN , MURTAZA ANWAR , TARCSA EDIT , STINE WILLIAM B , HSIEH CHUNG-MING

IPC: C07K16/18 , A61K39/395 , C07K16/46 , C12N15/13

Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.

53.

发明专利
Endothelin anatagonists 未知

公开(公告)号：AU2008201198A1

公开(公告)日：2008-04-03

申请号：AU2008201198

申请日：2008-03-12

Applicant: ABBOTT LAB

Inventor： SZCZEPANKIEWICZ BRUCE G , WITTENBERGER STEVEN J , JAE HWAN-SOO , BOYD STEVEN A , KESTER JEFFREY A , KING STEVEN A , WINN MARTIN , HENRY KENNETH J , LIU GANG , TASKER ANDREW S , HUTCHINS CHARLES W , SORENSEN BRYAN K , GELDEM THOMAS W VON

IPC: C07D405/00

54.

发明专利
未知

公开(公告)号：DK0885215T3

公开(公告)日：2006-08-14

申请号：DK97905816

申请日：1997-02-12

Applicant: ABBOTT LAB

Inventor： WINN MARTIN , VON GELDERN THOMAS W , SORENSEN BRYAN K , LIU GANG , BOYD STEVEN A , HUTCHINS CHARLES W , JAE HWAN-SOO , TASKER ANDREW S , KESTER JEFFREY A , SZCZEPANKIEWICZ BRUCE G , HENRY KENNETH J JR , WITTENBERGER STEVEN J , KING STEVEN A

IPC: C07D405/04 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/4035 , A61K31/41 , A61K31/415 , A61K31/4164 , A61K31/4166 , A61K31/421 , A61K31/425 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/495 , A61K31/506 , A61K31/675 , A61P1/00 , A61P1/04 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P11/00 , A61P11/06 , A61P13/12 , A61P25/06 , A61P43/00 , C07D207/16 , C07D211/60 , C07D401/04 , C07D403/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D419/14 , C07D453/02 , C07D471/04 , C07D491/04 , C07F9/572 , C07F9/59

Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

55.

发明专利
Benzo-1, 3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists 未知

公开(公告)号：NZ514170A

公开(公告)日：2005-02-25

申请号：NZ51417097

申请日：1997-02-12

Applicant: ABBOTT LAB

Inventor： WINN MARTIN , BOYD STEVEN A , HUTCHINS CHARLES W , JAE HWAN SOO , TASKER ANDREW S , VON GELDERN THOMAS V , KESTER JEFFREY A , SORENSEN BRYAN K , SZCZEPANKIEWICZ BRUCE G , HENRY KENNETH J , LIU GANG , WITTENBERGER STEVEN J , KING STEVEN A

IPC: A61K31/40 , A61P9/00 , A61P19/00 , C07D207/16 , C07D401/04 , C07D405/04 , C07D405/14 , C07F9/572

Abstract: A process for preparing a compound of formula (I), wherein: E is a carboxy-protecting group and R1 and R2 are loweralkyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl,aminocarbonyalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, heterocyclic and (heterocyclic)alkyl Wherein cycloalkyl, aryl and heterocyclic may be optionally substituted, provided at least one of the following conditions apply: (a) R1 is selected from haloalkyl, haloalkoxyalkyl, cycloalkylalkyl, arylalkyl, aryloxyalkyl, and (heterocyclic)alkyl, (b) R2 is selected from haloalkyl, haloalkoxyalkyl, cycloalkylalkyl, arylalkyl, aryloxyalkyl, (c) at least on of the optionally substituted aryl groups has at least on substituent selected from hydroxyalkyl and cyano or (d) at least one of the optionally substituted heterocyclic groups has at least one substituent selected from alkyloxycarbonyl, nitro and cyano; comprises a) catalytic hydrogenation of a compound of Formula (II) b)catalytic hydrogenation of the product of step a) in the presence of an acid or a mixture of acids, and c) epimerization of the product of step b) with a base. Also described is the compound (2R, 3R, 4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl-aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid. This compound can be used in the manufacture of a medicament for antagonizing endothelin treating hypertension, congestive heart failure, restinosis cerebral or myocardial ischemia or atherosclerosis, treating coronary angina, cerebral vasospasm, acute and chronic renal failure, gastric ulceration, cyclosporine-induced nephrotoxicity, endotoxin-induced toxicity, asthma, LPL-related lipoprotein disorders, proliferative diseases, acute or chronic pulmonary hypertension, platelet aggregation, thrombosis, IL-2 mediated cardio toxicity nociception, colitis, vascular permeability disorders, ischemia-reperfusion injury raynaud's disease, migraine and for treating bone pain. (62) Divided out of 503365